Researchers of a multicenter, randomized, assessor-blinded trial across 13 Italian dermatology clinics evaluated whether adding a novel oral supplement enhances outcomes for androgenetic alopecia (AGA) and female AGA. Two hundred twenty-five adults (mean age 40; 18–74 years) with mild–severe disease received either pharmacologic therapy plus daily AGA-P (n=106) or pharmacologic therapy alone (n=119). The primary endpoint was the proportion achieving “much improved” on a 7-point Global Assessment Scale at 6 months, rated by a blinded assessor using standardized vertex photographs. Safety and tolerability were monitored via adverse events and patient-reported outcomes.
Adjunct AGA-P produced a higher rate of marked improvement versus drugs alone (36.5% vs 25.0%; P=0.04), suggesting the supplement may increase the clinical efficacy of standard therapy. While the study tracked safety, detailed adverse-event results were not described here. The authors recommend larger, confirmatory trials to validate efficacy, refine safety characterization, and clarify the role of supplementation within AGA treatment strategies.
Reference: Smith T. Dietary Supplement Increases Efficacy of Pharmacological Treatments for Androgenic Alopecia. HCP Live. Published August 25, 2025. Accessed September 17, 2025. https://www.hcplive.com/view/dietary-supplement-increases-efficacy-pharmacological-treatments-androgenic-alopecia
Link: https://www.hcplive.com/view/dietary-supplement-increases-efficacy-pharmacological-treatments-androgenic-alopecia
